Expert Roundtable: Racial Disparities in Dermatology Care
A roundtable discussion by experts in issues facing patients with skin of color reveals interesting insights.
A roundtable discussion by experts in issues facing patients with skin of color reveals interesting insights.
The racial and ethnic distribution of common dermatologic disorders seen at a US tertiary care center are characterized.
One of the largest case series of intranasal butorphanol rescue therapy in treating intractable itch demonstrates success.
In a multivariable logistic regression, PN and LSC were associated with having 1 or more mental health disorders.
Menlo Therapeutics announced topline results from two phase 3 studies of serlopitant for the treatment of pruritus associated with prurigo nodularis.
Nemolizumab was associated with a greater reduction in pruritus and severity of skin lesions compared with placebo in patients with prurigo nodularis.
The off-label use of treatments is especially prevalent in dermatology as the need for effective therapies outpaces the approval process. Experts discuss the most commonly employed treatments, the ethical implications of off-label use, and the need for patient education.
Nemolizumab is a first-in-class humanized monoclonal antibody that blocks the signaling of IL-31 by targeting IL-31 receptor alpha.
Black patients with HIV may be at increased risk for pruritic disorders compared with race-matched controls and white patients with HIV.
A new review provides evidence-based guidance for practitioners treating the dermatologic condition prurigo nodularis and highlights gaps in treatment development and research.